- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00557830
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC.
The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Clopton Clinic
-
-
California
-
La Verne, California, Estados Unidos, 91750
- Wilshire Oncology Medical Group, Inc.
-
-
Florida
-
Miami, Florida, Estados Unidos, 33176
- Advanced Medical Specialties
-
-
Georgia
-
Athens, Georgia, Estados Unidos, 30607
- Northeast Georgia Cancer Care
-
Atlanta, Georgia, Estados Unidos, 30309
- Peachtree Hematology Oncology Consultants
-
Macon, Georgia, Estados Unidos, 31201
- Central Georgia Cancer Care
-
Marietta, Georgia, Estados Unidos, 30060
- Northwest Georgia Oncology Centers
-
-
Illinois
-
Normal, Illinois, Estados Unidos, 61761
- Mid-Illinois Hematology and Oncology Associates, Ltd.
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- Hematology Oncology Centers of the Northern Rockies
-
-
North Carolina
-
Gastonia, North Carolina, Estados Unidos, 28054
- Gaston Hematology and Oncology
-
-
Oregon
-
Beaverton, Oregon, Estados Unidos, 97006
- Pacific Oncology, PC
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Estados Unidos, 17605
- The Lancaster Cancer Center, Ltd
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38120
- The West Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years old.
- Diagnosis of unresectable/metastatic renal cell carcinoma (RCC). Nonclear cell histology is permitted (except for medullary, collecting duct, or sarcomatoid >50% of specimen). Prior metastasectomy is permitted as long as there is measurable disease at time of consent.
- Karnofsky Performance Status of 50% or greater at study entry.
- Adequate bone marrow, liver and renal function as assessed by the following: o Hemoglobin ≥ 9.0 g/dL. o ANC ≥ 1500/mm3. o Platelet count ≥ 100,000/mm3. o Total bilirubin ≤ 1.5 ULN. o ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver involvement). o Creatinine ≤ 1.5 × ULN.
- Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatment.
- Women of childbearing potential and sexually active men must agree to use adequate barrier contraception prior to study entry, for the duration of study participation, and for at least three months after the last administration of sorafenib.
- INR < 1.5 or a PT/ PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
- Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
Exclusion Criteria:
- Prior systemic anticancer treatment for metastatic disease, including investigational therapy.
- Prior treatment with bevacizumab, sunitinib, or sorafenib even in the adjuvant setting.
- Prior cytokine therapy with interleukin (IL)-2 or interferon (IFN) for metastatic disease.
- Active malignancy other than RCC (except non-melanoma skin cancer) within 5 years of enrollment.
- Hemodialysis or peritoneal dialysis.
- Treatment with radiotherapy within 2 weeks of enrollment.
- Cardiac disease: Congestive heart failure Class II or higher per NYHA. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
- Uncontrolled CNS metastases. All patients must undergo a CT) scan/MRI of the brain to exclude brain metastasis. Patients with adequately treated CNS disease may be considered for participation as long as the first dose of sorafenib is 4 weeks after completion of CNS therapy.
- Uncontrolled hypertension defined as SBP > 150 mmHg or DBP > 90 mmHg, despite optimal medical management.
- Active clinically serious infection > Grade 2 per the CTCAE v3.
- Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- Pulmonary hemorrhage/bleeding event ≥ Grade 2 per CTCAE v3.0 within 4 weeks of administration of the first dose of study drug.
- Any other hemorrhage/bleeding event ≥ Grade 3 per CTCAE v3.0 within 4 weeks of administration of the first dose of study drug.
- Serious non-healing wound, ulcer, or bone fracture.
- Evidence or history of bleeding diathesis or coagulopathy.
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of administration of the first study drug dose.
- Use of St. John's Wort, rifampin (rifampicin), phenytoin, Phenobarbital, carbamazepine, dexamethasone.
- Known or suspected allergy to sorafenib or any agent given in the course of this trial.
- Any condition that impairs patient's ability to swallow whole pills.
- Any malabsorption problem.
- Pregnancy or lactation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Group A: Escalated Dose
Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen).
Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2).
Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
|
Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2).
Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
Otros nombres:
|
Comparador activo: Group B: Standard Dose
Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen).
Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
|
Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Response Rate (CR + PR) Determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.
Periodo de tiempo: Overall response will be measured at baseline and every 8 weeks , unless clinically indicated prior to that, until the end of treatment.
|
Response was evaluated via changes from baseline in radiological tumor measurements performed every 8 weeks and at the end of treatment unless clinically indicated prior to that.
Confirmatory scans were to be obtained no less than 4 weeks but no more than 6 weeks following initial documentation of objective response.
Response was evaluated using RECIST criteria, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions or the appearance of one or more new lesions.
|
Overall response will be measured at baseline and every 8 weeks , unless clinically indicated prior to that, until the end of treatment.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
PFS Rate at 9, 13 and 17 Months
Periodo de tiempo: PFS was to be measured at 9, 13, and 17 months.
|
Due to the early study closure and the small sample size, the PFS rate at 9, 13, and 17 months were not evaluated.
|
PFS was to be measured at 9, 13, and 17 months.
|
Overall Survival Rate
Periodo de tiempo: Overall survival was measured from day 1 of treatment until the end of treatment and then every 4 months thereafter until death.
|
Due to the early study closure and the small sample size, overall survival rate was not evaluated.
|
Overall survival was measured from day 1 of treatment until the end of treatment and then every 4 months thereafter until death.
|
Changes From Baseline in Symptom Burden
Periodo de tiempo: The PCM was administered during screening, at each scheduled visit (approximately every 4 weeks), and at the end of treatment visit.
|
The Patient Care Monitor Version 2.0 (PCM) is an tablet computer based assessment system that measures patient reported outcomes (PROs) in medical patients with a particular emphasis on symptoms related to cancer and its treatment. The PCM comprises 86 items which include 8 items answered only by females (e.g. menstrual cramping). Each item is presented so that the patient rates the degree to which the item has been a problem in the past week (0 not a problem to 10 as bad as possible). |
The PCM was administered during screening, at each scheduled visit (approximately every 4 weeks), and at the end of treatment visit.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Vasily Assikis, MD, Acorn Cardiovascular, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades Renales
- Enfermedades urológicas
- Adenocarcinoma
- Neoplasias Glandulares y Epiteliales
- Neoplasias Renales
- Carcinoma De Célula Renal
- Carcinoma
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Sorafenib
Otros números de identificación del estudio
- AVJARCC0702
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Carcinoma de células renales
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and Kidney... y otros colaboradoresReclutamientoEnfermedades Renales Crónicas | Fallo renal agudo | Lesión renal aguda | Insuficiencia Renal Aguda | Insuficiencia renal cronica | Insuficiencia Renal, Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia renal aguda | Insuficiencia Renal Crónica | Enfermedades... y otras condicionesEstados Unidos
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillTerminadoEnfermedades Renales Crónicas | Enfermedad Renal Crónica Etapa 5 | Enfermedad Renal Crónica etapa 4 | Enfermedad renal pediátrica | Enfermedad Renal Crónica etapa 3 | Enfermedad Renal Crónica Etapa V | Enfermedad renal crónica, estadio IV (grave) | Enfermedad Renal Crónica Etapa 2 | Enfermedad Renal...Estados Unidos
-
University Hospital, BordeauxMinistry of Health, FranceTerminadoTrasplante Renal | Enfermedad renal crónica en etapa terminal | Insuficiencia Renal Aguda SeveraFrancia
-
Faculdade de Ciências Médicas da Santa Casa de...TerminadoEnfermedad Renal Crónica | Diálisis renalBrasil
-
Wake Forest University Health SciencesStanford UniversityTerminadoTrasplante Renal | Rechazo Renal Agudo | Rechazo Renal Crónico | Rechazo de Trasplante Renal | Sistema Renina-AngiotensinaEstados Unidos
-
Outset MedicalTerminadoLesión renal aguda | Enfermedad renal en etapa terminal (ESRD) | Enfermedad renal en etapa terminal en diálisisEstados Unidos
-
Novartis PharmaceuticalsTerminadoHemodiálisis | Terapia de reemplazo renal | Enfermedad renal en etapa terminal (ESRD) | Trasplante Renal | Enfermedad renal crónica (ERC)Alemania, Estados Unidos, Bélgica, Italia, España, Croacia, Taiwán, Australia, Austria, Grecia, Corea, república de, Líbano, Chequia, Israel, Países Bajos, Eslovenia, Suiza, Tailandia, Noruega, Pavo, Suecia, Argentina, Brasil, Japón, Serbia, Federación Rusa y más
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)TerminadoFallo renal agudo | Insuficiencia renal cronicaAustria
-
ArdelyxAstraZenecaTerminadoEnfermedad renal en etapa terminal | ESRD | Enfermedad Renal Crónica Etapa 5Estados Unidos
-
Angiodynamics, Inc.TerminadoEnfermedad Renal Crónica | Lesión renal aguda | Fallo renal agudo | Insuficiencia renal crónica inducida por contrasteEstados Unidos
Ensayos clínicos sobre Sorafenib Escalated Dose
-
University of South CarolinaMedical University of South Carolina; National Institute on Deafness and Other...Terminado
-
University of MinnesotaReclutamientoTrasplante de órganos sólidosEstados Unidos
-
Dose Safety Inc.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Benaroya...SuspendidoGlucosa, sangre baja | Glucosa, sangre altaEstados Unidos
-
Memorial Sloan Kettering Cancer CenterActivo, no reclutandoTumores sólidos | Entrenamiento aeróbico preoperatorioEstados Unidos
-
BayerAmgenTerminado
-
Technical University of MunichTerminadoCarcinoma de células renalesAustria, Alemania, Países Bajos
-
Ottawa Hospital Research InstituteBayerTerminadoCáncer colorrectal metastásicoCanadá
-
Ohio State University Comprehensive Cancer CenterBayerTerminado
-
British Columbia Cancer AgencyRetiradoCarcinomas de células escamosas de cabeza y cuello localmente avanzados (SCCHN)Canadá
-
Yiviva Inc.ReclutamientoCarcinoma hepatocelular avanzadoEstados Unidos, Taiwán, Porcelana, Hong Kong